The expression “liver function tests” is widely used, but the panel contains measurements with different biological meanings. ALT, AST, alkaline phosphatase, and GGT are enzyme activities associated with patterns of injury or cholestasis; albumin and coagulation measures relate more directly to hepatic synthetic function; bilirubin reflects production, uptake, conjugation, and excretion. An assay guide should preserve these distinctions rather than describing every abnormal result as a direct measure of liver function.
From a reagent-development perspective, liver testing is also unusual because the enzyme may be the measurand. In an ALT or ALP activity assay, the patient's endogenous enzyme initiates the reaction, while reagent enzymes and synthetic substrates translate that activity into a measurable rate. The composition and timing of the measurement procedure therefore define the reported catalytic activity.
Our product offerings: Liver Function Assay Enzymes
| Measurement | Analytical Category | What the Method Detects | Important Limitation |
|---|---|---|---|
| ALT | Endogenous enzyme activity | Alanine aminotransferase-catalyzed reaction under defined conditions | Activity depends on substrate, cofactor, temperature, timing, and standardization. |
| AST | Endogenous enzyme activity | Aspartate aminotransferase-catalyzed reaction under defined conditions | AST is also present in muscle and other tissues; it is not liver-specific. |
| ALP | Endogenous enzyme activity | Hydrolysis of a phosphate substrate at alkaline pH | Serum activity can arise from liver, bone, intestine, placenta, and other isoforms. |
| GGT | Endogenous enzyme activity | Gamma-glutamyl transfer to an acceptor substrate | Elevations are not specific to one disease or mechanism. |
| Bilirubin | Small-molecule analyte | Total or direct-reacting bilirubin by chemical or enzymatic approaches | Hemolysis, light exposure, drug effects, and method-dependent fractions matter. |
| Total bile acids | Metabolite group | Commonly a 3-alpha-hydroxysteroid dehydrogenase-linked response | Different bile-acid species may not respond identically. |
| Albumin and PT/INR | Protein concentration and coagulation measurement | Non-enzyme-activity measures used in functional assessment | They are influenced by conditions beyond liver disease. |
ALT catalyzes transfer of an amino group from L-alanine to 2-oxoglutarate, producing pyruvate and L-glutamate. In a common coupled method, lactate dehydrogenase converts pyruvate to lactate while oxidizing NADH. The decrease in NADH absorbance is monitored kinetically and is related to ALT activity.
AST transfers an amino group from L-aspartate to 2-oxoglutarate, producing oxaloacetate and L-glutamate. Malate dehydrogenase can convert oxaloacetate to malate while oxidizing NADH. Some systems include lactate dehydrogenase to consume endogenous pyruvate and reduce background.
The observed NADH rate should follow the patient enzyme activity rather than the capacity of LDH or MDH. Auxiliary enzymes are therefore supplied in catalytic excess under the assay conditions. Their activity specifications should be based on performance in the reagent matrix, not only on supplier units measured in a different buffer.
Aminotransferases require pyridoxal-5'-phosphate (PLP). Methods may include PLP to activate apoenzyme forms, and this can change measured activity. Results from methods with and without PLP supplementation may not be directly comparable. The reagent, reference interval, calibration approach, and performance claims should use one defined procedure.
ALP methods commonly monitor hydrolysis of 4-nitrophenyl phosphate at alkaline pH, producing a colored product. Magnesium and zinc ions are important to catalytic function, while buffer identity, pH, temperature, substrate concentration, and sample fraction strongly affect activity. The IFCC reference procedure at 37°C specifies a defined set of reaction conditions for catalytic concentration measurement.
ALP illustrates why an enzyme activity is a method-defined measurand. Changing buffer or pH can alter isoform response and total activity. Chelating anticoagulants can also affect metal-dependent activity, making specimen type and collection requirements important.
GGT methods generally use a gamma-glutamyl donor substrate and an acceptor such as glycylglycine. Transfer releases a chromogenic product that can be monitored kinetically. Substrate purity, spontaneous hydrolysis, acceptor concentration, pH, and temperature influence blank and rate.
GGT is often used with ALP to help contextualize a cholestatic laboratory pattern, but analytical and clinical specificity should not be confused. A well-performing GGT assay quantifies catalytic activity according to its procedure; it does not by itself identify a single disease.
Bilirubin is not an enzyme. Many routine methods use diazo chemistry, while some approaches use bilirubin oxidase or other enzymatic reactions. Total and direct-reacting bilirubin fractions are method-defined, and “direct bilirubin” does not simply equal chemically pure conjugated bilirubin in every procedure. Light exposure can lower bilirubin concentration, and hemolysis or turbidity may interfere with optical detection.
Total bile-acid methods commonly use 3-alpha-hydroxysteroid dehydrogenase. The enzyme oxidizes the 3-alpha-hydroxyl group while reducing a nicotinamide cofactor. Cycling systems may amplify the signal by repeatedly regenerating substrate and cofactor states. Cycling improves sensitivity but also increases the need to control reagent blank, cofactor purity, auxiliary reaction balance, and species-dependent response.
Enzyme catalytic activity changes with temperature and other reaction conditions. Converting a result measured at one temperature to another with a universal factor is unreliable because temperature response can vary by enzyme, isoform, specimen, and method. Reference procedures define measurement at a specified temperature, commonly 37°C, with controlled timing and composition.
Traceability for an enzyme activity method requires more than a conventional analyte calibrator. Laboratories and manufacturers may use reference measurement procedures, reference materials or control materials with assigned values, and method-comparison hierarchies. The routine method must maintain a documented relationship to its claimed reference system.
| Risk | Most Relevant Measurements | Possible Effect | Control Strategy |
|---|---|---|---|
| Hemolysis | AST, LDH-coupled systems, bilirubin, optical assays | Release of intracellular activities and hemoglobin-related spectral or chemical effects | Define hemolysis limits and test concentration-dependent bias. |
| EDTA, citrate, or oxalate | ALP and metal-dependent reactions | Chelation changes catalytic activity | Validate specimen types; do not assume plasma and serum equivalence. |
| Endogenous pyruvate or oxaloacetate | ALT and AST coupled methods | Initial NADH consumption unrelated to target activity | Use preincubation or auxiliary-enzyme design appropriate to the method. |
| Light exposure | Bilirubin | Photodegradation and negative bias | Control collection, transport, and storage exposure. |
| Substrate blank | GGT, ALP, cycling assays | Nonenzymatic signal drift | Control reagent purity, pH, temperature, and blank correction. |
| Macroenzymes or isoforms | Selected enzyme activity measurements | Persistent or atypical activity patterns | Recognize that routine total-activity methods do not identify every molecular form. |
Coupling enzymes in ALT and AST reagents should be qualified differently from the endogenous enzyme being measured. LDH and MDH raw materials need sufficient activity under the finished-reagent conditions, low interfering side activities, predictable NADH blank behavior, and stability with substrates and preservatives. Their release limits should protect the patient-enzyme measurement without making specifications unnecessarily dependent on a supplier assay conducted under unrelated conditions.
For ALP and GGT, the most critical raw materials may be synthetic substrates, buffers, metal salts, acceptors, and stabilizers rather than a reagent enzyme. Qualification should follow the reaction risk: verify substrate identity and purity, spontaneous hydrolysis, pH control, trace-metal contamination, and lot-to-lot blank. This prevents an enzyme-centered purchasing checklist from overlooking the component that actually controls assay drift.
AASLD describes ALT and AST primarily as markers of hepatocellular injury, whereas ALP and GGT can support evaluation of cholestatic patterns. Bilirubin, albumin, and coagulation measures provide different information. The magnitude of an enzyme elevation should not be equated automatically with the extent of tissue damage, and an assay-development resource should not provide diagnosis from a single result.
The appropriate goal for a reagent developer is analytical: a defined, traceable, precise, linear, and interference-characterized measurement procedure. Clinical interpretation belongs to the combination of results, reference intervals or decision limits, history, examination, imaging, and professional judgment.
